Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21293396 | 1.00 | CYP11B1 (0.31) | CYP11B1CYP11B2HSD17B10LMNAGLA | |
| SCHEMBL8387811 | 0.79 | TRPA1 (0.38) | CYP11B1CYP11B2LMNA | |
| SCHEMBL8387805 | 0.79 | TRPA1 (0.38) | CYP11B1CYP11B2LMNA | |
| SCHEMBL5322803 | 0.79 | CYP11B1 (0.36) | CYP11B1CYP11B2 | |
| SCHEMBL21293618 | 0.78 | HCAR2 (0.40) | LMNAMAPTSMN1; SMN2 | |
| SCHEMBL21293732 | 0.76 | MAP3K7 (0.33) | CYP11B1CYP11B2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL8387605 | 0.75 | CYP11B1 (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL8386884 | 0.75 | CYP11B1 (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL8386858 | 0.75 | CYP11B1 (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL8386856 | 0.75 | CYP11B1 (0.32) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008312-B2 | Pyridazine derivatives as RORc modulators | GENENTECH, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3535255-A1 | PYRIDAZINE DERIVATIVES AS RORC MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2019-09-11 | — | — | EP | disclosed |
| US-20190263794-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008312-B2 | Pyridazine derivatives as RORc modulators | RORC, RORB, RORA | CYP11B1 392/4885CYP11B2 491/4885HSD17B10 3267/4885 |
| US-20190263794-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | CYP11B1 392/4885CYP11B2 491/4885HSD17B10 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.